Across TCGA pan-cancer cohorts, RPL7P25 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL7P25’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RPL7P25 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL7P25 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LIHC, and LUSC are the cancer types where RPL7P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.039	.006	2	view →
LIHC	All	All	+0.019	.035	2	view →
LUSC	Female	III,IV	−0.135	.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPL7P25 RNA expression & survival · all RPL7P25 data types